These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31702498)

  • 1. An Investigation of the Anti-Parkinsonism Potential of Co-enzyme Q
    Onaolapo OJ; Odeniyi AO; Jonathan SO; Samuel MO; Amadiegwu D; Olawale A; Tiamiyu AO; Ojo FO; Yahaya HA; Ayeni OJ; Onaolapo AY
    Curr Aging Sci; 2021; 14(1):62-75. PubMed ID: 31702498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Evaluation of the Effects of Pyridoxal Phosphate in Chlorpromazineinduced Parkinsonism using Mice.
    Olofinnade AT; Onaolapo TM; Oladimeji S; Fatoki AM; Balogun CI; Onaolapo AY; Onaolapo OJ
    Cent Nerv Syst Agents Med Chem; 2020; 20(1):13-25. PubMed ID: 31987026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effect of diclofenac on chlorpromazine induced catalepsy in rats.
    Naeem S; Najam R; Khan SS; Mirza T; Sikandar B
    Metab Brain Dis; 2019 Aug; 34(4):1191-1199. PubMed ID: 31055785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism.
    Abdin AA; Hamouda HE
    Neuropharmacology; 2008 Dec; 55(8):1340-6. PubMed ID: 18817789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Inflammatory, Anti-Oxidant, and Anti-Lipaemic Effects of Daily Dietary Coenzyme-Q10 Supplement in a Mouse Model of Metabolic Syndrome.
    Onaolapo OJ; Omotoso SA; Olofinnade AT; Onaolapo AY
    Antiinflamm Antiallergy Agents Med Chem; 2021; 20(4):380-388. PubMed ID: 33906592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary zinc supplement militates against ketamine-induced behaviours by age-dependent modulation of oxidative stress and acetylcholinesterase activity in mice.
    Onaolapo OJ; Jegede OR; Adegoke O; Ayinde MO; Akeredolu OM; Onaolapo AY
    Pharmacol Rep; 2020 Feb; 72(1):55-66. PubMed ID: 32016846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease.
    Safirstein BE; Ellenbogen A; Zhao P; Henney HR; Kegler-Ebo DM; Oh C
    Clin Ther; 2020 Jun; 42(6):1034-1046. PubMed ID: 32482490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary coenzyme Q10 and vitamin E alter the status of these compounds in rat tissues and mitochondria.
    Ibrahim WH; Bhagavan HN; Chopra RK; Chow CK
    J Nutr; 2000 Sep; 130(9):2343-8. PubMed ID: 10958833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amlodipine, an L-type calcium channel blocker, protects against chlorpromazine-induced neurobehavioural deficits in mice.
    Kale OE; Awodele O; Ogundare TF; Ekor M
    Fundam Clin Pharmacol; 2017 Jun; 31(3):329-339. PubMed ID: 28103649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NSAIDs ameliorate cognitive and motor impairment in a model of parkinsonism induced by chlorpromazine.
    Naeem S; Ikram R; Khan SS; Rao SS
    Pak J Pharm Sci; 2017 May; 30(3):801-808. PubMed ID: 28653925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of M. chamomilla L. tea on chlorpromazine induced catalepsy: A neuroprotective study.
    Khan SS; Ikram R; Naeem S; Khatoon H; Anser H; Sikander B
    Pak J Pharm Sci; 2020 Sep; 33(5):1945-1953. PubMed ID: 33824100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1.
    Kabel AM; Omar MS; Alhadhrami A; Alharthi SS; Alrobaian MM
    Physiol Behav; 2018 May; 188():108-118. PubMed ID: 29410018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial anti-Parkinson effects of camel milk in Chlorpromazineinduced animal model: Behavioural and histopathological study.
    Khatoon H; Najam R; Mirza T; Sikandar B
    Pak J Pharm Sci; 2016 Sep; 29(5):1525-1529. PubMed ID: 27731807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haloperidol-induced parkinsonism is attenuated by varenicline in mice.
    Sharma AK; Gupta S; Patel RK; Wardhan N
    J Basic Clin Physiol Pharmacol; 2018 Jul; 29(4):395-401. PubMed ID: 29634484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbidopa/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats.
    Arica B; Kaş HS; Moghdam A; Akalan N; Hincal AA
    J Control Release; 2005 Feb; 102(3):689-97. PubMed ID: 15681090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
    Tetrud J; Nausieda P; Kreitzman D; Liang GS; Nieves A; Duker AP; Hauser RA; Farbman ES; Ellenbogen A; Hsu A; Kell S; Khanna S; Rubens R; Gupta S
    J Neurol Sci; 2017 Feb; 373():116-123. PubMed ID: 28131167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules.
    Modi NB; Mittur A; Rubens R; Khanna S; Gupta S
    Clin Neuropharmacol; 2019; 42(1):4-8. PubMed ID: 30520758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rapid non invasive L-DOPA-¹³C breath test for optimally suppressing extracerebral AADC enzyme activity - toward individualizing carbidopa therapy in Parkinson’s disease.
    Modak A; Durso R; Josephs E; Rosen D
    J Parkinsons Dis; 2012; 2(4):349-56. PubMed ID: 23646099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson's disease--In relation to the effects of Mucuna pruriens.
    Nagashima Y; Kondo T; Sakata M; Koh J; Ito H
    J Neurol Sci; 2016 Feb; 361():229-34. PubMed ID: 26810548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.